Results 211 to 220 of about 48,920 (248)
Some of the next articles are maybe not open access.
Current Treatment Options in Cardiovascular Medicine, 2001
Angiographic restenosis occurs in 30% to 50% of patients after percutaneous transluminal coronary angioplasty (PTCA) with 20% to 30% target vessel revascularization at one year, and is associated with increased morbidity, mortality and health care costs. Intracoronary stents are the first line of therapy against restenosis after angioplasty.
Mehran, Moussavian +2 more
openaire +2 more sources
Angiographic restenosis occurs in 30% to 50% of patients after percutaneous transluminal coronary angioplasty (PTCA) with 20% to 30% target vessel revascularization at one year, and is associated with increased morbidity, mortality and health care costs. Intracoronary stents are the first line of therapy against restenosis after angioplasty.
Mehran, Moussavian +2 more
openaire +2 more sources
Current Cardiology Reports, 2000
This review provides an overview of candidate genes that are currently being evaluated for genetic strategies in vascular gene therapy. We discuss treatment strategies that have proven efficacious in limiting postinterventional restenosis through evaluation with in vivo model systems.
R C, Smith, K, Walsh
openaire +2 more sources
This review provides an overview of candidate genes that are currently being evaluated for genetic strategies in vascular gene therapy. We discuss treatment strategies that have proven efficacious in limiting postinterventional restenosis through evaluation with in vivo model systems.
R C, Smith, K, Walsh
openaire +2 more sources
Prevention of Coronary Restenosis
Cardiology in Review, 1999Percutaneous transluminal coronary angioplasty (PTCA) was introduced 22 years ago as a nonsurgical catheter-based treatment for obstructive coronary artery disease. Over the following 2 decades, major advances in equipment and techniques led to tremendous growth in the use of PTCA to treat coronary artery disease and angina.
P J, Casterella, P S, Teirstein
openaire +2 more sources
RESTENOSIS OF THE MITRAL VALVE
Annals of Internal Medicine, 1957Excerpt Restenosis of the mitral valve is a new clinical entity which has been made possible by the recent advances in cardiac surgery.
G E, MUEHSAM, O, AUERBACH
openaire +2 more sources
The Pathophysiology and Burden of Restenosis
The American Journal of Cardiology, 2007The introduction of percutaneous transluminal coronary angioplasty (PTCA) revolutionized the surgical treatment of coronary artery disease. However, despite increased surgical experience and technical breakthroughs, restenosis occurs in 30%-50% of patients undergoing simple balloon angioplasty and in 10%-30% of patients who receive an intravascular ...
openaire +2 more sources
Trends in Cardiovascular Medicine, 1994
Percutaneous transluminal coronary angioplasty is a widely used technique for recanalizing arteries that are occluded by atherosclerotic plaque, but its usefulness is limited by the occurrence ofrestenosis in a high proportion of patients. The development of new therapies for this currently intractable problem will be facilitated by the use of animal ...
openaire +2 more sources
Percutaneous transluminal coronary angioplasty is a widely used technique for recanalizing arteries that are occluded by atherosclerotic plaque, but its usefulness is limited by the occurrence ofrestenosis in a high proportion of patients. The development of new therapies for this currently intractable problem will be facilitated by the use of animal ...
openaire +2 more sources
New England Journal of Medicine, 2002
Over the past two decades, percutaneous coronary intervention has revolutionized the treatment of symptomatic coronary artery disease, sparing countless patients the need for surgical revascularization. This year, up to a million procedures are likely to be performed in North America alone. The success of percutaneous coronary intervention has been due
openaire +2 more sources
Over the past two decades, percutaneous coronary intervention has revolutionized the treatment of symptomatic coronary artery disease, sparing countless patients the need for surgical revascularization. This year, up to a million procedures are likely to be performed in North America alone. The success of percutaneous coronary intervention has been due
openaire +2 more sources